Aldeyra Therapeutics reports results from phase IIa study of ADX-102 in dry eye disease Sep. 13, 2017 No Comments
Editas Medicine initiates clinical natural history study in patients with LCA10 Sep. 13, 2017 No Comments
Primary endpoint not met in SPECTRI study of lampalizumab for geographic atrophy Sep. 13, 2017 No Comments
Apellis' phase II study of APL-2 in geographic atrophy meets primary endpoint Aug. 25, 2017 No Comments
Response submitted to FDA's complete response letter for latanoprostene bunod Aug. 18, 2017 No Comments
Shire's lifitegrast marketing authorization application validated in Europe Aug. 17, 2017 No Comments
Phase III study of Fovista in wet age-related macular degeneration does not meet primary endpoint Aug. 16, 2017 No Comments
Israel Innovation Authority grants USD 2 million to Biotime to develop OpRegen Aug. 16, 2017 No Comments
RSS